Overview
Thymus Extract (Thymostimulin) is a partially purified preparation of thymic polypeptides derived from calf thymus tissue, first developed in Italy in 1976. It contains a heterogeneous mixture of peptides with molecular weights ranging from 1 to 12 kDa that stimulate T-cell differentiation and maturation. It has been investigated for immune support in cancer patients, surgical patients, and those with chronic infections.
Mechanism of action
Thymus Extract contains a complex mixture of thymic hormones and peptides including thymosin fractions, thymulin-like peptides, and other thymic factors that collectively regulate T-lymphocyte development and immune homeostasis. These peptides stimulate T-cell differentiation and maturation in the thymus, regulate natural killer (NK) cell activity, modulate dendritic cell function, and induce the release of pro-inflammatory cytokines in appropriate contexts. By restoring thymic output of mature T-lymphocytes, thymic extracts are proposed to compensate for age-related thymic involution and the progressive immunosenescence that accompanies it. Individual peptide fractions within the extract include precursors to thymosin alpha-1, thymopoietin, and thymulin, though the exact composition varies between preparations and batches due to biological variation in the extraction process.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| immune support research | intramuscular | 25–150 mg | twice weekly for 4–6 weeks | European clinical trial protocols used 25–150 mg IM doses. Exact dosing varies by preparation batch standardization. |
| subcutaneous research use | subcutaneous | 10–50 mg | twice to three times weekly | Subcutaneous dosing used in some protocols; concentration and bioavailability varies by preparation. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Thymostimulin has been studied in clinical trials for reducing infections in surgical patients, supporting immune function in cancer patients undergoing chemotherapy, and treating chronic or recurrent infections. Initial evidence suggests reduced infection incidence in at-risk patient populations. A 1991 BioDrugs review summarized evidence from European clinical trials showing T-cell reconstitution and reduced infection rates. No large, modern Phase 3 RCTs have been completed meeting contemporary standards. Thymus Extract preparations lack standardization by active components, making cross-study comparison difficult. Interest has shifted toward isolated thymic peptides (thymosin alpha-1, thymalin) with defined compositions.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Thymus Extract for synergistic effects.
Legal status
Not FDA-approved as a pharmaceutical. Thymostimulin was investigated in Europe and the US but never received FDA NDA approval. Thymosin alpha-1 (a defined component) is separately approved in some countries. Available in Western markets as a research substance or supplement. Not for therapeutic human use.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.